Parkinson's Disease Neuroprotection Clinical Centers

描述(由申请人提供)：如本RFA(RFA-NS-02-010)公告中所述，该项目的目标是创建一个临床中心，用于进行未来帕金森氏病神经保护的临床试验。该网站有三名接受过运动障碍培训的委员会认证的神经学家，他们将参与这个拟议的项目。在这个项目实施后，这些神经学家将合作进行一种药物的试点试验，以防止帕金森病的疾病进展。随后，与其他临床中心站点的进一步合作将导致至少一项多中心试验。 该项目将有助于为管理与帕金森氏症相关的神经保护的临床试验(S)维护稳定的基础设施。此外，这种类型的临床试验的进行(S)将产生一个可能愿意参与基因研究的早期帕金森病患者的样本。同样，受试者可能愿意参与从血液或脑脊液中识别可能指示疾病存在或严重程度的标志物的研究。这项研究可能会导致对帕金森病的更好理解和更好的治疗。

DESCRIPTION (provided by applicant): As outlined in this RFA (RFA-NS-02-010) announcement, the aims of this project are to create a clinical center for the conduct of future clinical trials of neuroprotection for Parkinson's disease. This site has three board-certified neurologists trained in movement disorders who will participate in this proposed project. Upon implementation of this project these neurologists will collaborate to conduct a pilot trial of an agent to prevent disease progression in PD. Subsequently, additional collaboration with the other clinical center sites will lead to at least one multicenter trial. This project will help to maintain a stable infrastructure for the administration of the clinical trial(s) in neuroprotection related to Parkinson's disease. In addition, the conduct of this type of clinical trial(s) will generate a sample of patients with early PD who may be willing to participate in genetic studies. Similarly, subjects may be willing to participate in studies to identify markers from blood or cerebrospinal fluid that may indicate disease presence or severity. This research may lead to a greater understanding of PD and better treatments.